BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Aug 23, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling TrkB fusion oncogenes and mutations could help predict sensitivity to the TrkA/TrkB/TrkC inhibitor larotrectinib in patients with blood cancers. Genomic sequencing of 7,311 patients with hematologic malignancies identified one TrkA, one TrkB...
BioCentury | Jun 1, 2018
Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
BioCentury | May 30, 2018
Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Nov 17, 2017
Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
Items per page:
1 - 10 of 24